Perspective Therapeutics partners with Merck to test [212Pb]PSV359 with Keytruda in FAP-α-positive solid tumors
CATX•Study and supply details
Merck will supply pembrolizumab at no cost, and Perspective will sponsor the trial.
The study has completed enrollment in the first three monotherapy dose cohorts.
Merck collaboration and supply agreement
Perspective Therapeutics entered a clinical trial collaboration and supply agreement with Merck to test [212Pb]PSV359 with Keytruda (pembrolizumab).
Trial expansion in FAP-α-positive solid tumors
The combination will be evaluated via an amendment to Perspective’s ongoing Phase 1/2a study in FAP-α-positive non-small cell lung cancer and colorectal cancer.
